BioVaxys Technology Corp.
OTC: BVAXF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James Christopher Passin
- Employees
- 3
- Headquarters
- Etobicoke, Canada
- IPO year
- 2018
- Market cap
- $3.8M
- Website
- https://www.biovaxys.com
Loading BVAXF…
Loading profile data…Frequently asked questions about BVAXF
What does BioVaxys Technology Corp. (BVAXF) do?
BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company primarily engaged in the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Its product pipeline features several key candidates, including two SARS-CoV-2 vaccines: BVX-0320, a monovalent version, and BVX-0121, a mu...
Where does BVAXF trade?
BioVaxys Technology Corp. (BVAXF) trades on the Other OTC.
What sector is BVAXF in?
BioVaxys Technology Corp. (BVAXF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BioVaxys Technology Corp.?
James Christopher Passin is the chief executive officer of BioVaxys Technology Corp. (BVAXF).
Where is BioVaxys Technology Corp. headquartered?
BioVaxys Technology Corp. is headquartered in Canada.
Does BVAXF pay a dividend?
BioVaxys Technology Corp. (BVAXF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BVAXF go public?
BioVaxys Technology Corp. (BVAXF) completed its initial public offering in 2018.